Blog Archives
A case report of 2100+ days of long-term paediatric VAD therapy
Ventricular assist devices (VADs) have been placed as destination therapy in adults for over twenty years but have only recently been considered an option in a subset of paediatric patients. A 2016 report from the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS) revealed only eight paediatric patients implanted as destination therapy. Here, the authors … [Read more]
Evaluating diagnostic rates and relative frequencies of LGMD using targeted NGS
This study aimed to study the diagnostic value of targeted next-generation sequencing (NGS) in limb-girdle muscular dystrophies (LGMDs), and investigate the mutational spectrum of Chinese LGMD patients. Targeted NGS covering 420 genes in 180 patients who were consecutively suspected of LGMDs and underwent muscle biopsies from January 2013 to May 2015. The association between … [Read more]
Efficacy of AAV-mediated transfer of FKRP in a mouse model
Limb Girdle Muscular Dystrophies type 2I (LGMD2l), a recessive autosomal muscular dystrophy, is caused by mutations in the Fukutin Related Protein (FKRP) gene. It has been proposed that FKRP, a ribitol-5-phosphate transferase, is a participant in α-dystroglycan (αDG) glycosylation, which is important to ensure the cell/matrix anchor of muscle fibers. A LGMD2l knock-in mouse … [Read more]
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy
Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). The authors of the present study have recently shown in a 12-month double-blind randomised controlled trial that adding eplerenone to background medical therapy was cardioprotective in this population. Here, they evaluated the safety and efficacy of longer-term eplerenone therapy … [Read more]
SMA: Positive opinion of the EMA for Spinraza™
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Spinraza™, a first step towards market authorisation. The European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP) issued a positive opinion on the Marketing Authorisation Application (MAA) in Europe for Spinraza™ (or nusinersen) … [Read more]
Mutations in INPP5K mutations and Congenital Muscular Dystrophy
Congenital muscular dystrophies display a wide phenotypic and genetic heterogeneity. The combination of clinical, biochemical, and molecular genetic findings must be considered to obtain the precise diagnosis and provide appropriate genetic counselling. Here, the authors report five individuals from four families presenting with variable clinical features including muscular dystrophy with a reduction in dystroglycan … [Read more]
Rigid spine syndrome associated with sensory-motor axonal neuropathy resembling Charcot-Marie-Tooth disease
BAG3 (Bcl-2 associated athanogene-3) mutations have been described in rare cases of rapidly progressive myofibrillar myopathies. Symptoms begin in the first decade with axial involvement and contractures and are associated with cardiac and respiratory impairment in the second decade. Axonal neuropathy has been documented, but usually not as a key clinical feature. Here, the … [Read more]
Electrical impedance myography (EIM) in individuals with COL6 and LAMA2 congenital muscular dystrophy
Electrical impedance myography (EIM) is a non-invasive electrophysiological technique that characterises muscle properties through bioimpedance. This study compared EIM measurements to function, strength, and disease severity in 41 patients with congenital muscular dystrophy (CMD). They had either collagen 6 related disorders (COL6-RD) (n = 21) or laminin alpha 2-related disorders (LAMA2-RD) (n = 20) … [Read more]
Rescue of dystrophin expression and recovery of the conduction system in the heart of dystrophic dogs by PPMO-mediated multiexon skipping
Duchenne muscular dystrophy (DMD) is a lethal genetic disorder caused by an absence of the dystrophin protein in bodywide muscles, including the heart. Cardiomyopathy is a leading cause of death in DMD. Exon skipping via synthetic phosphorodiamidate morpholino oligomers (PMOs) represents one of the most promising therapeutic options, yet PMOs have shown very little … [Read more]
Unilateral oculomotor palsy in Charcot-Marie-Tooth disease 1A (CMT 1A)
Charcot-Marie-Tooth disease (CMT) type 1A is the most common form of CMT 1 and one of the autosomal dominant demyelinating hereditary motor and sensory neuropathies (HMSN). Cranial nerves may be frequently subclinically affected in CMT disease. However manifest clinical signs of cranial nerve involvement are rare. This case comprises neurological, ophthalmological, internal medicine and … [Read more]